Description
Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy.
